By Billy Candra 
Researchers at the Francis Crick Institute, the UCL Cancer Institute, and UCLH have unveiled a groundbreaking test named ORACLE, demonstrating its superior ability to predict lung cancer survival at the point of diagnosis compared to existing clinical risk factors. This significant advancement holds the potential to revolutionize treatment decisions for individuals diagnosed with stage 1 lung cancer, promising to reduce the risk of recurrence or metastatic spread. The findings, published in the prestigious journal Nature Cancer, represent a pivotal step towards more personalized and effective therapeutic strategies for one of the world’s most challenging cancers.
The study, which evaluated ORACLE in 158 lung cancer patients as part of the Cancer Research UK-funded TRACERx study, found that the novel test provided a more accurate prognosis of patient survival than currently employed clinical standards, such as tumour stage. This breakthrough addresses a critical unmet need in lung cancer management, particularly for those diagnosed at an early stage, where current predictive tools often fall short.
The Persistent Challenge of Lung Cancer and the Need for Better Tools
Lung cancer stands as the leading cause of cancer-related death globally, responsible for an estimated 1.8 million fatalities worldwide in 2020, according to the International Agency for Research on Cancer (IARC). Despite advances in screening, diagnosis, and treatment over recent decades, the prognosis for lung cancer patients remains grim, with five-year survival rates significantly lower than many other common cancers. In the UK, while overall cancer survival has doubled in the last 50 years, progress for lung cancer, though improved since the 1970s, has not kept pace with other malignancies. This stark reality underscores the urgent need for innovative diagnostic and prognostic tools that can precisely stratify patient risk and guide tailored interventions.
A major hurdle in lung cancer treatment, especially for early-stage disease, is the inherent heterogeneity of tumours. When doctors take a biopsy sample from a tumour, they typically capture less than 1% of the entire mass. The genetic makeup and biological characteristics can vary dramatically from one region to another within the same tumour. This "snapshot" approach often fails to provide a comprehensive picture of the tumour’s true aggressiveness or its potential for spread, leading to suboptimal treatment decisions for a significant proportion of patients.
This issue is particularly pronounced in individuals with stage 1 lung cancer. Conventionally, these patients are treated with surgery alone, often without adjuvant chemotherapy, given the assumption of localized disease. However, for a worrying one-quarter of stage 1 patients, their cancer ultimately returns or metastasizes. This suggests that these individuals, despite their early diagnosis, might have benefited from more intensive monitoring, targeted chemotherapy, or alternative therapeutic approaches from the outset. The absence of reliable biological markers to identify these high-risk stage 1 patients has long been a critical gap in clinical practice, leaving clinicians to rely on broader, less precise indicators.
The Genesis of ORACLE: A Novel Approach to Tumour Heterogeneity
ORACLE was initially developed in 2019 with the explicit aim of overcoming this pervasive lack of robust biological markers in lung cancer. Its innovative design directly confronts the challenge of tumour heterogeneity by moving beyond the limitations of single-point biopsies. Instead of focusing on a small, potentially unrepresentative sample, ORACLE analyzes genes expressed at either high or low levels across multiple regions within the entire tumour. This comprehensive genomic profiling allows it to capture a more accurate and holistic understanding of the tumour’s biological landscape, providing insights into its potential for progression and response to therapy.
The development of ORACLE represents a significant methodological leap. Traditional genomic analyses often provide a ‘consensus’ view of a tumour, which can mask critical intra-tumoural variations that drive disease progression. By meticulously examining gene expression across different tumour regions, ORACLE effectively maps the genetic diversity within a single malignancy. This detailed genetic fingerprint allows researchers to identify subtle yet crucial biological signals that indicate a tumour’s inherent aggressiveness, its likelihood of spreading, and its potential responsiveness to specific drugs. The researchers’ pioneering work has brought the concept of ‘cancer evolution’ – understanding how cancers adapt and change over time and space – directly into the realm of clinical application.
Unpacking the Study’s Key Findings and Their Clinical Ramifications
The recent Nature Cancer publication meticulously details ORACLE’s superior predictive capabilities across several critical dimensions:
1. Enhanced Survival Prediction: The core finding confirms ORACLE’s ability to predict patient survival more accurately than established clinical standards, including tumour stage. This enhanced prognostic power is invaluable for risk stratification, allowing clinicians to identify patients who may require more aggressive or tailored interventions earlier in their treatment journey.
2. Identifying High-Risk Stage 1 Patients: Crucially, ORACLE demonstrated its unique capacity to identify stage 1 lung cancer patients who had a lower chance of survival. This group, which current clinical standards fail to adequately distinguish, could potentially benefit significantly from adjuvant chemotherapy in addition to surgery, or from more frequent and intensive post-operative monitoring. This offers a pathway to prevent the recurrence that affects a quarter of these early-stage patients.
3. Predicting Metastatic Potential: The study further revealed a compelling link between high ORACLE risk scores and regions of the tumour that were more likely to spread to other parts of the body. This predictive insight into metastatic potential provides an early warning system, enabling proactive strategies to manage or prevent the dissemination of cancer cells, which is often the primary cause of mortality in cancer patients.
4. Guiding Chemotherapy Selection: Perhaps one of the most immediate and impactful clinical applications of ORACLE lies in its ability to predict drug response. The researchers discovered that a high ORACLE risk score correlated with a better response to certain types of chemotherapy, particularly platinum-based drugs such as cisplatin. This finding is rooted in the underlying biology: tumour regions with high ORACLE scores are frequently associated with ‘chromosomal instability’ – a state of extensive genomic alteration where the DNA is highly unstable. Platinum drugs are known to exert their cytotoxic effects by damaging DNA, making chromosomally unstable cells particularly vulnerable to their action. This mechanistic understanding is reinforced by previous research from the same lab, which identified changes in a key gene called FAT1 as a driver of chromosomal instability, a genetic variation that ORACLE specifically seeks out.
Yun-Hsin Liu, a Research Assistant at the UCL Cancer Institute and co-first author of the study, emphasized the comprehensive nature of these findings: "We wanted to build on the previous work developing ORACLE and show that it can predict survival at the point of a lung cancer diagnosis. We’ve also shown that it can predict who would benefit from certain types of chemotherapy drugs or if someone’s cancer is likely to spread, giving a holistic measure of how a patient’s cancer might progress and respond." This ‘holistic measure’ represents a significant departure from fragmented diagnostic information, offering a unified view of a patient’s disease trajectory and therapeutic vulnerabilities.
The Road Ahead: Validation and Clinical Translation
While the initial results from the TRACERx study are highly promising, the researchers are keen to emphasize that further validation is essential before ORACLE can be widely adopted in clinical practice. The immediate next steps involve larger, prospective studies designed to compare outcomes in patients with high ORACLE scores who receive standard care versus those who receive enhanced surveillance or additional chemotherapy. This crucial comparative analysis will determine if the implementation of ORACLE genuinely improves survival rates, even for individuals diagnosed at the earliest stages of the disease.
The journey from a research breakthrough to a clinically available diagnostic tool is complex and requires significant collaboration. Charles Swanton, Deputy Clinical Director and Head of the Cancer Evolution and Genome Instability Laboratory at the Crick, Chief Investigator for TRACERx, and co-senior author of the study, articulated this vision: "Lung cancer is the leading cause of cancer-related death throughout the world, so it’s clear we need better markers to accurately classify tumours and predict who is at high risk. We’re now working with the Translation team at the Crick and industry partners to progress ORACLE into a test which could hopefully be used in the clinic as soon as possible."
The Translation team at the Crick, specifically led by Paul Mercer, Head of Industry Partnerships, is actively engaged in bridging this gap. Mercer noted, "This is an important step forward, translating our understanding of the infinite complexities of lung cancer mutation into a diagnostic tool, prioritising patients for the most effective therapies. We look forward to working with partners to take this work forward and maximise patient benefit from ORACLE." These efforts underscore the commitment to ensuring that this scientific innovation translates into tangible benefits for patients as quickly and safely as possible.
Broader Implications: Reshaping Personalized Medicine in Oncology
The development and validation of ORACLE carry profound implications that extend beyond lung cancer, potentially setting a new paradigm for personalized medicine in oncology.
1. Enhanced Precision in Treatment Selection: ORACLE’s ability to predict both disease progression and drug response moves clinicians closer to truly personalized treatment plans. Instead of a ‘one-size-fits-all’ approach, doctors could tailor therapies based on the unique molecular signature of each patient’s tumour, maximizing efficacy while minimizing unnecessary treatments and their associated toxicities. This precision could spare low-risk patients from aggressive treatments they don’t need, while ensuring high-risk patients receive the intensified care they desperately require.
2. Impact on Early Detection and Intervention: By better identifying high-risk individuals even at stage 1, ORACLE could redefine the management of early-stage lung cancer. This could lead to earlier and more targeted interventions, potentially preventing the progression to advanced, often incurable, stages. For a disease where early detection is paramount but often insufficient, this represents a crucial advantage.
3. Driving Future Drug Development: The mechanistic insights provided by ORACLE, particularly its link to chromosomal instability and responsiveness to platinum drugs, could also inform future drug discovery efforts. Pharmaceutical companies might prioritize the development of novel agents that specifically target the biological pathways associated with high ORACLE scores, leading to more effective therapies for a significant subset of lung cancer patients.
4. A Paradigm Shift in Tumour Understanding: ORACLE’s success in overcoming tumour heterogeneity challenges the traditional view of cancer as a monolithic entity. It reinforces the understanding that tumours are complex, evolving ecosystems. This evolutionary perspective, where genetic variations and spatial heterogeneity dictate clinical outcomes, is increasingly recognized as fundamental to understanding and treating cancer effectively. ORACLE brings this advanced understanding directly into a practical diagnostic framework.
Dani Edmunds, Science Engagement Manager at Cancer Research UK, summarized the broader impact: "New tests to predict lung cancer’s behaviour could help doctors tailor treatment strategies to each person’s condition, giving the best chance of a successful outcome… While ORACLE still needs testing in larger-scale trials, these initial results show it could take us a step closer to more personalised approaches to treating lung cancer, so more people live longer, better lives."
The research was also supported by the National Institute for Health and Care Research UCLH Biomedical Research Centre, highlighting the collaborative effort across multiple institutions to bring this vital innovation to fruition. As the scientific community awaits the outcomes of larger validation studies, ORACLE stands as a beacon of hope, promising a future where lung cancer treatment is not only more informed but also profoundly more effective.
